Our Customer Services
ImmuNova BioMed is committed to advancing immunotherapy through cutting-edge nanotechnology. Our goal is to develop nanovaccine immunotherapy and immunomodulators that enhance the body’s natural immune response against cancer, infectious diseases, and autoimmune disorders—providing safer, more effective, and personalized treatment options.
1- Custom RNA and Peptide Engineering
We offer design and synthesis of high-purity, custom RNA and peptide molecules for a range of therapeutic, diagnostic, and research applications.
Service Highlights:
In silico RNA and peptide design
Targeted molecules for oncology, infectious, and immune-related diseases
Custom modifications (e.g., conjugations, tags)
RNA stability enhancement and delivery optimization
Peptides for biomarker detection and imaging
2- Nanoparticle-Based Delivery Platforms
We develop advanced nanoparticle systems for the precise and controlled delivery of RNA, peptides, and therapeutic agents.
Service Highlights:
Formulation of nanoparticles for mRNA, siRNA, and miRNA delivery
Targeted cancer therapeutics using smart delivery systems
Co-delivery of therapeutic and diagnostic agents (theranostics)
Antigen/RNA loading and controlled release
Preclinical testing for immunogenicity and efficacy
3- Personalized Nanovaccine Development
Using proprietary self-assembling nanovaccine platforms, we create customized vaccines for cancer immunotherapy and infectious disease prevention.
Service Highlights:
RNA-based vaccines for cancer, infectious, and autoimmune diseases
Tumor-specific antigen inclusion for personalized therapies
Controlled-release formulations for optimized immune response
Compatibility with various RNA types and active compounds
4- AI-Driven Immunotherapy Solutions
We apply AI technologies to design personalized RNA and peptide-based therapies that align with individual immune profiles.
Service Highlights:
Patient-specific RNA and peptide sequence design
AI-powered predictive models for therapy optimization
Custom checkpoint inhibitors (e.g., PD-1/PD-L1, CTLA-4)
Mimetic peptides and RNA-based expression systems
Preclinical proof-of-concept and efficacy studies
